CORCEPT THERAPEUTICS INC (CORT) Stock Fundamental Analysis
NASDAQ:CORT - Nasdaq - US2183521028 - Common Stock - Currency: USD
CORT gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 198 industry peers in the Pharmaceuticals industry. CORT scores excellent points on both the profitability and health parts. This is a solid base for a good stock. CORT is not priced too expensively while it is growing strongly. Keep and eye on this one! With these ratings, CORT could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
In the past year CORT was profitable.
In the past year CORT had a positive cash flow from operations.
Each year in the past 5 years CORT has been profitable.
Each year in the past 5 years CORT had a positive operating cash flow.
1.2 Ratios
CORT's Return On Assets of 16.80% is amongst the best of the industry. CORT outperforms 96.97% of its industry peers.
Looking at the Return On Equity, with a value of 20.78%, CORT belongs to the top of the industry, outperforming 92.42% of the companies in the same industry.
CORT has a better Return On Invested Capital (16.89%) than 92.93% of its industry peers.
CORT had an Average Return On Invested Capital over the past 3 years of 17.94%. This is significantly below the industry average of 42.34%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.8% | ||
| ROE | 20.78% | ||
| ROIC | 16.89% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
1.3 Margins
The Profit Margin of CORT (20.92%) is better than 93.43% of its industry peers.
CORT's Profit Margin has declined in the last couple of years.
Looking at the Operating Margin, with a value of 20.29%, CORT belongs to the top of the industry, outperforming 85.86% of the companies in the same industry.
In the last couple of years the Operating Margin of CORT has declined.
CORT has a Gross Margin of 98.39%. This is amongst the best in the industry. CORT outperforms 97.47% of its industry peers.
In the last couple of years the Gross Margin of CORT has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 20.29% | ||
| PM (TTM) | 20.92% | ||
| GM | 98.39% |
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
2. Health
2.1 Basic Checks
CORT has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
The number of shares outstanding for CORT has been increased compared to 1 year ago.
CORT has less shares outstanding than it did 5 years ago.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 32.68 indicates that CORT is not in any danger for bankruptcy at the moment.
CORT has a Altman-Z score of 32.68. This is amongst the best in the industry. CORT outperforms 95.96% of its industry peers.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 32.68 |
ROIC/WACC1.71
WACC9.87%
2.3 Liquidity
A Current Ratio of 3.35 indicates that CORT has no problem at all paying its short term obligations.
CORT's Current ratio of 3.35 is in line compared to the rest of the industry. CORT outperforms 58.08% of its industry peers.
CORT has a Quick Ratio of 3.26. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.26, CORT is in the better half of the industry, outperforming 61.62% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.35 | ||
| Quick Ratio | 3.26 |
3. Growth
3.1 Past
CORT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.43%, which is quite good.
Measured over the past years, CORT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.71% on average per year.
CORT shows a strong growth in Revenue. In the last year, the Revenue has grown by 39.94%.
Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 17.11% on average per year.
EPS 1Y (TTM)9.43%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-32%
Revenue 1Y (TTM)39.94%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%7.09%
3.2 Future
The Earnings Per Share is expected to grow by 54.37% on average over the next years. This is a very strong growth
CORT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 29.15% yearly.
EPS Next Y13.31%
EPS Next 2Y47.92%
EPS Next 3Y70.13%
EPS Next 5Y54.37%
Revenue Next Year29.79%
Revenue Next 2Y32.48%
Revenue Next 3Y32.46%
Revenue Next 5Y29.15%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 65.34 indicates a quite expensive valuation of CORT.
CORT's Price/Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 78.28% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.03, CORT is valued quite expensively.
CORT is valuated quite expensively with a Price/Forward Earnings ratio of 27.94.
CORT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 72.73% of the companies in the same industry.
CORT's Price/Forward Earnings ratio indicates a valuation a bit more expensive than the S&P500 average which is at 21.94.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.34 | ||
| Fwd PE | 27.94 |
4.2 Price Multiples
CORT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CORT is cheaper than 76.77% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CORT is valued a bit cheaper than 78.28% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.03 | ||
| EV/EBITDA | 53.48 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates CORT does not grow enough to justify the current Price/Earnings ratio.
CORT has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CORT's earnings are expected to grow with 70.13% in the coming years.
PEG (NY)4.91
PEG (5Y)6.73
EPS Next 2Y47.92%
EPS Next 3Y70.13%
5. Dividend
5.1 Amount
CORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
75.8
-0.42 (-0.55%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners82.09%
Inst Owner Change-1.62%
Ins Owners6.52%
Ins Owner Change0.39%
Market Cap8.04B
Analysts82
Price Target142.29 (87.72%)
Short Float %14.06%
Short Ratio7.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.17%
Min EPS beat(2)-40.2%
Max EPS beat(2)42.54%
EPS beat(4)3
Avg EPS beat(4)12.54%
Min EPS beat(4)-40.2%
Max EPS beat(4)42.54%
EPS beat(8)6
Avg EPS beat(8)14.58%
EPS beat(12)8
Avg EPS beat(12)7.58%
EPS beat(16)11
Avg EPS beat(16)8.96%
Revenue beat(2)1
Avg Revenue beat(2)-3.09%
Min Revenue beat(2)-10.25%
Max Revenue beat(2)4.07%
Revenue beat(4)3
Avg Revenue beat(4)-0.2%
Min Revenue beat(4)-10.25%
Max Revenue beat(4)4.07%
Revenue beat(8)6
Avg Revenue beat(8)0.89%
Revenue beat(12)7
Avg Revenue beat(12)-0.9%
Revenue beat(16)8
Avg Revenue beat(16)-1.83%
PT rev (1m)-2.11%
PT rev (3m)86.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-68.85%
EPS NY rev (1m)-18.73%
EPS NY rev (3m)-34.64%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.24%
Revenue NY rev (1m)-0.7%
Revenue NY rev (3m)10.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 65.34 | ||
| Fwd PE | 27.94 | ||
| P/S | 11.91 | ||
| P/FCF | 41.03 | ||
| P/OCF | 40.58 | ||
| P/B | 11.83 | ||
| P/tB | 11.83 | ||
| EV/EBITDA | 53.48 |
EPS(TTM)1.16
EY1.53%
EPS(NY)2.71
Fwd EY3.58%
FCF(TTM)1.85
FCFY2.44%
OCF(TTM)1.87
OCFY2.46%
SpS6.37
BVpS6.41
TBVpS6.41
PEG (NY)4.91
PEG (5Y)6.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 16.8% | ||
| ROE | 20.78% | ||
| ROCE | 19.57% | ||
| ROIC | 16.89% | ||
| ROICexc | 37.58% | ||
| ROICexgc | 37.58% | ||
| OM | 20.29% | ||
| PM (TTM) | 20.92% | ||
| GM | 98.39% | ||
| FCFM | 29.02% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexcg growth 3Y-18.86%
ROICexcg growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.8
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 162.57% | ||
| Cap/Sales | 0.32% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 143.23% | ||
| Profit Quality | 138.73% | ||
| Current Ratio | 3.35 | ||
| Quick Ratio | 3.26 | ||
| Altman-Z | 32.68 |
F-Score6
WACC9.87%
ROIC/WACC1.71
Cap/Depr(3y)72.82%
Cap/Depr(5y)100.78%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)9.43%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-32%
EPS Next Y13.31%
EPS Next 2Y47.92%
EPS Next 3Y70.13%
EPS Next 5Y54.37%
Revenue 1Y (TTM)39.94%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%7.09%
Revenue Next Year29.79%
Revenue Next 2Y32.48%
Revenue Next 3Y32.46%
Revenue Next 5Y29.15%
EBIT growth 1Y27.55%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year9.57%
EBIT Next 3Y47.28%
EBIT Next 5Y19.15%
FCF growth 1Y54.37%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y55.91%
OCF growth 3Y5.66%
OCF growth 5Y7.79%